IL274701B2 - Promote drugs, compositions and methods of their use - Google Patents
Promote drugs, compositions and methods of their useInfo
- Publication number
- IL274701B2 IL274701B2 IL274701A IL27470120A IL274701B2 IL 274701 B2 IL274701 B2 IL 274701B2 IL 274701 A IL274701 A IL 274701A IL 27470120 A IL27470120 A IL 27470120A IL 274701 B2 IL274701 B2 IL 274701B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims 15
- 229960003624 creatine Drugs 0.000 title claims 7
- 239000006046 creatine Substances 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 53
- 150000003839 salts Chemical class 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000003003 spiro group Chemical group 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004450 alkenylene group Chemical group 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 6
- 229910003002 lithium salt Inorganic materials 0.000 claims 6
- 159000000002 lithium salts Chemical class 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 102000004420 Creatine Kinase Human genes 0.000 claims 3
- 108010042126 Creatine kinase Proteins 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 3
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 208000016361 genetic disease Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 3
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229940054136 kineret Drugs 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593731P | 2017-12-01 | 2017-12-01 | |
| PCT/US2018/063580 WO2019109067A2 (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274701A IL274701A (en) | 2020-06-30 |
| IL274701B1 IL274701B1 (en) | 2024-03-01 |
| IL274701B2 true IL274701B2 (en) | 2024-07-01 |
Family
ID=66665277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274701A IL274701B2 (en) | 2017-12-01 | 2018-12-03 | Promote drugs, compositions and methods of their use |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11332438B2 (https=) |
| EP (1) | EP3717453A4 (https=) |
| JP (2) | JP7433226B2 (https=) |
| KR (1) | KR102678696B1 (https=) |
| CN (1) | CN111417620B (https=) |
| AR (1) | AR118403A1 (https=) |
| AU (1) | AU2018375199B2 (https=) |
| BR (1) | BR112020010805B1 (https=) |
| CO (1) | CO2020006542A2 (https=) |
| IL (1) | IL274701B2 (https=) |
| MX (1) | MX2020005707A (https=) |
| SG (1) | SG11202004336VA (https=) |
| TW (1) | TWI815832B (https=) |
| WO (1) | WO2019109067A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102678696B1 (ko) * | 2017-12-01 | 2024-06-27 | 울트라제닉스 파마수티컬 인코포레이티드 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
| US11383694B1 (en) | 2021-08-13 | 2022-07-12 | Oshkosh Defense, Llc | Electrified military vehicle |
| WO2024136952A1 (en) * | 2022-12-20 | 2024-06-27 | Florida Atlantic University Board Of Trustees | Phosphagen system modulators and uses thereof |
| US20250017886A1 (en) * | 2023-07-06 | 2025-01-16 | Vireo Systems, Inc. | Formulations and methods for increasing creatinine levels in plasma, extracellular fluid and/or intracellular compartments |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7319157B1 (en) * | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
| JP2013028562A (ja) * | 2011-07-28 | 2013-02-07 | Mitsubishi Paper Mills Ltd | ナノファイバー形成化合物、ナノファイバーの形成方法およびナノファイバー集合体の形成方法 |
| WO2015031712A1 (en) * | 2013-08-30 | 2015-03-05 | Momentive Performance Materials Inc. | Moisture curable compound with amino acids |
| WO2016110822A1 (en) * | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Carboxylic biacyl creatine derivative, uses and method of synthesis thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0718000B2 (ja) | 1985-05-15 | 1995-03-01 | 日本真空技術株式会社 | 合成樹脂被膜の形成方法 |
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0595894B1 (en) | 1991-07-19 | 1995-12-20 | UNIROYAL CHEMICAL COMPANY, Inc. | Seed film compositions |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| JPH0718000A (ja) * | 1993-06-18 | 1995-01-20 | Takeda Chem Ind Ltd | 新規ペプチド |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| AU4151996A (en) | 1994-11-08 | 1996-05-31 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| AU721190B2 (en) | 1995-10-11 | 2000-06-29 | Avicena Group, Inc. | Use of creatine analogues for the treatment of disorders of glucose metabolism |
| US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6008252A (en) | 1996-07-26 | 1999-12-28 | Beale; Paxton K. | Method for increasing muscle mass in a mammal |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US20030008007A1 (en) | 2001-04-23 | 2003-01-09 | Jose Gutierrez-Rocca | Release pharmaceutical construct for gastric retention |
| US20030013767A1 (en) | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2002363998A1 (en) | 2001-12-15 | 2003-06-30 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| EP1478345A4 (en) | 2002-01-03 | 2010-11-17 | Glaxosmithkline Llc | NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS |
| DE10221344A1 (de) | 2002-05-14 | 2003-12-04 | Hannover Med Hochschule | Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung |
| MXPA04011325A (es) * | 2002-05-16 | 2005-02-14 | Bayer Cropscience Gmbh | Derivados de piridina-carboxamida y su uso como plaguicidas. |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| US20040126366A1 (en) | 2002-06-04 | 2004-07-01 | Rima Kaddurah-Daouk | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| WO2004002445A2 (en) | 2002-06-26 | 2004-01-08 | Cadila Healthcare Limited | Novel floating dosage form |
| US20040120983A1 (en) | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US8106093B2 (en) | 2004-07-02 | 2012-01-31 | Baylor Research Institute | Glycogen or polysaccharide storage disease treatment method |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
| US20070012105A1 (en) | 2005-07-13 | 2007-01-18 | Barnes-Jewish Hospital | Method and apparatus for resistive characteristic assessment |
| US20070032750A1 (en) | 2005-07-15 | 2007-02-08 | Jeffrey Oster | Muscle strength assessment system |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| WO2007146085A2 (en) | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine phosphate prodrugs, compositions and uses thereof |
| US20070281995A1 (en) | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine analog prodrugs, compositions and uses thereof |
| AU2007332800A1 (en) | 2006-12-07 | 2008-06-19 | Avicena Group, Inc. | Creatine compositions for skin treatment |
| WO2008101310A1 (en) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2008101309A1 (en) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| US8426395B2 (en) | 2008-05-30 | 2013-04-23 | Northern Northern Innovations Holding Corp | Preparations containing creatine and imino sugars |
| WO2010005692A2 (en) | 2008-06-16 | 2010-01-14 | E. I. Du Pont De Nemours And Company | Insecticidal cyclic carbonyl amidines |
| WO2010074591A1 (ru) | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Амиды креатина, способ их получения, средство, обладающее нейропротекторным действием |
| CA2785714C (en) | 2009-12-30 | 2016-01-26 | Baylor Research Institute | Anaplerotic therapy for alzheimer's disease and the aging brain |
| CN103079555A (zh) | 2010-06-14 | 2013-05-01 | 贝勒研究院 | 用于成人葡萄糖多聚体病（apbd）治疗的三庚酸甘油酯膳食 |
| HK1200459A1 (en) | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| EP2692719B1 (en) | 2012-07-30 | 2016-06-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof |
| ITTO20121098A1 (it) | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| US20160289175A1 (en) * | 2013-11-05 | 2016-10-06 | Ultragenyx Pharmaceutical Inc. | Creatine analogs and the use thereof |
| ITTO20131070A1 (it) | 2013-12-24 | 2015-06-25 | Univ Degli Studi Genova | Applicazione terapeutica di un derivato di creatina |
| US9642825B2 (en) | 2014-02-27 | 2017-05-09 | 4141 Holdings, Llc | Bio-available N-acetyl creatine species and compositions thereof |
| EP3194370A4 (en) | 2014-09-03 | 2018-01-24 | Lumos Pharma, Inc. | Synthesis of cyclocreatine and analogs thereof |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
| KR102678696B1 (ko) | 2017-12-01 | 2024-06-27 | 울트라제닉스 파마수티컬 인코포레이티드 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
-
2018
- 2018-12-03 KR KR1020207018932A patent/KR102678696B1/ko active Active
- 2018-12-03 MX MX2020005707A patent/MX2020005707A/es unknown
- 2018-12-03 SG SG11202004336VA patent/SG11202004336VA/en unknown
- 2018-12-03 AU AU2018375199A patent/AU2018375199B2/en active Active
- 2018-12-03 BR BR112020010805-7A patent/BR112020010805B1/pt active IP Right Grant
- 2018-12-03 JP JP2020527818A patent/JP7433226B2/ja active Active
- 2018-12-03 AR ARP180103527A patent/AR118403A1/es unknown
- 2018-12-03 WO PCT/US2018/063580 patent/WO2019109067A2/en not_active Ceased
- 2018-12-03 US US16/764,969 patent/US11332438B2/en active Active
- 2018-12-03 IL IL274701A patent/IL274701B2/en unknown
- 2018-12-03 CN CN201880077165.5A patent/CN111417620B/zh active Active
- 2018-12-03 TW TW107143208A patent/TWI815832B/zh active
- 2018-12-03 EP EP18883842.9A patent/EP3717453A4/en active Pending
-
2020
- 2020-05-28 CO CONC2020/0006542A patent/CO2020006542A2/es unknown
-
2022
- 2022-03-28 US US17/706,283 patent/US11753369B2/en active Active
-
2023
- 2023-07-14 US US18/352,959 patent/US20240092731A1/en active Pending
- 2023-09-20 JP JP2023152930A patent/JP7542705B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7319157B1 (en) * | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
| JP2013028562A (ja) * | 2011-07-28 | 2013-02-07 | Mitsubishi Paper Mills Ltd | ナノファイバー形成化合物、ナノファイバーの形成方法およびナノファイバー集合体の形成方法 |
| WO2015031712A1 (en) * | 2013-08-30 | 2015-03-05 | Momentive Performance Materials Inc. | Moisture curable compound with amino acids |
| WO2016110822A1 (en) * | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Carboxylic biacyl creatine derivative, uses and method of synthesis thereof |
Non-Patent Citations (1)
| Title |
|---|
| DANIEL SAMAIN ET AL,, STRUCTURE OF SCOPAFUNGIN, A POTENT NONPOLYENE ANTIFUNGAL ANTIBIOTIC, 1 July 1982 (1982-07-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| AR118403A1 (es) | 2021-10-06 |
| SG11202004336VA (en) | 2020-06-29 |
| MX2020005707A (es) | 2020-08-20 |
| JP2024009811A (ja) | 2024-01-23 |
| AU2018375199A1 (en) | 2020-05-28 |
| BR112020010805A2 (pt) | 2020-11-10 |
| CN111417620A (zh) | 2020-07-14 |
| IL274701A (en) | 2020-06-30 |
| TWI815832B (zh) | 2023-09-21 |
| US20240092731A1 (en) | 2024-03-21 |
| CO2020006542A2 (es) | 2020-06-09 |
| JP2021505537A (ja) | 2021-02-18 |
| CA3082184A1 (en) | 2019-06-06 |
| IL274701B1 (en) | 2024-03-01 |
| WO2019109067A2 (en) | 2019-06-06 |
| WO2019109067A3 (en) | 2020-03-26 |
| US11332438B2 (en) | 2022-05-17 |
| BR112020010805B1 (pt) | 2024-01-30 |
| EP3717453A4 (en) | 2021-07-28 |
| JP7433226B2 (ja) | 2024-02-19 |
| US11753369B2 (en) | 2023-09-12 |
| US20220227703A1 (en) | 2022-07-21 |
| AU2018375199B2 (en) | 2023-03-30 |
| EP3717453A2 (en) | 2020-10-07 |
| TW201927368A (zh) | 2019-07-16 |
| US20210002211A1 (en) | 2021-01-07 |
| JP7542705B2 (ja) | 2024-08-30 |
| KR102678696B1 (ko) | 2024-06-27 |
| KR20200105833A (ko) | 2020-09-09 |
| CN111417620B (zh) | 2023-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274701B2 (en) | Promote drugs, compositions and methods of their use | |
| CY1117974T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| EA201170374A1 (ru) | Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний | |
| ES2601856T3 (es) | Inhibidores de la IRE-1A | |
| ES2679628T3 (es) | Composiciones novedosas, usos y métodos de su preparación | |
| JP2017537940A5 (https=) | ||
| JP2018523665A5 (https=) | ||
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| ES2963614T3 (es) | Derivado de p-fenilendiamina como regulador del canal de potasio y método de preparación y aplicación médica del mismo | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| AR078674A1 (es) | Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas | |
| EP1797099A1 (en) | Piperidinylamino-thieno[2,3-d] pyrimidine compounds | |
| HRP20211973T1 (hr) | Kinazolini kao inhibitori ionskih kalijskih kanala | |
| AR073209A1 (es) | Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen. | |
| PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| UY32562A (es) | Pirimidinas sustituidas por imidazol 724 | |
| AR066712A1 (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa, una composicion farmaceutica que las comprende y su uso en eltratamiento de enfermedades mediadas por la inhibicion de la sintesis del peptido beta-amiloide. | |
| AR131263A1 (es) | Compuestos de pirrolil-sulfonamida fusionados | |
| JP2021505537A5 (https=) | ||
| BRPI0808828A2 (pt) | compostos de dibenzo[b,f][1,4]oxazapina | |
| PE20251750A1 (es) | Inhibidores de hexahidro-2h-pirido[2,1-a]isoquinolina vmat2 y metodos de uso | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |